Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 nov. 2017 12h41 HE | Source: Verona Pharma plc

Block Listing Update

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
30 nov. 2017 08h42 HE | Source: Verona Pharma plc

PDMR Dealing

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
07 nov. 2017 02h00 HE | Source: Verona Pharma plc

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
07 nov. 2017 02h00 HE | Source: Verona Pharma plc

Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
31 oct. 2017 03h00 HE | Source: Verona Pharma plc

Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
31 oct. 2017 02h55 HE | Source: Verona Pharma plc

Verona Pharma to Present at Two Upcoming Investor Conferences

LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
02 oct. 2017 02h00 HE | Source: Verona Pharma plc

Total Voting Rights

UK DISCLOSURE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Total Voting Rights...
27 sept. 2017 02h00 HE | Source: Verona Pharma plc

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients

LONDON, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
19 sept. 2017 07h53 HE | Source: Verona Pharma plc

Issue of Shares

UK DISCLOSURE, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Issue of Shares...
07 sept. 2017 02h00 HE | Source: Verona Pharma plc

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Demonstrated statistical significance across all...

Page précédente